The Silicon Valley Bank has recently released its 2021 Semiannual Report on Global Healthcare Investment Activity.
According to the report, venture capital (VC) investment boomed in H1 2021, rising to $21.8 billion, driven by Venture Healthcare’s rapid response to the Corona pandemic. This surpassed Venture Healthcare’s record total from last year ($16.8 billion) by 25 percent.
While many of the VC firms raised opportunity funds, private equities and hedge funds jumped in with private equity funds in later rounds of funding. Leading these private investments were healthcare and biopharma, with a record $23.2 billion in the first quarter. In the second quarter, investments actually increased to 23.9 billion. Overall, the first half of 2021 saw twice as much total investment as the previous year at 47 billion.
The number of VC IPOs was similar to the full year 2020 (112) at 84, with the Research & Development (RD) Tools division dominating investments. Post-IPO performance was mixed, with RD and Dx Tools performing well and Healthcare and Biopharma performing worse.
Source: www.healthcare-startups.de